CN115093373A - 一种1,5-二取代-3-氟烷基-1,2,4-三氮唑化合物及其制备方法和应用 - Google Patents
一种1,5-二取代-3-氟烷基-1,2,4-三氮唑化合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN115093373A CN115093373A CN202211016094.2A CN202211016094A CN115093373A CN 115093373 A CN115093373 A CN 115093373A CN 202211016094 A CN202211016094 A CN 202211016094A CN 115093373 A CN115093373 A CN 115093373A
- Authority
- CN
- China
- Prior art keywords
- fluoroalkyl
- substituted
- triazole
- disubstituted
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 65
- 238000006243 chemical reaction Methods 0.000 claims abstract description 41
- 150000001875 compounds Chemical class 0.000 claims abstract description 12
- 125000000218 acetic acid group Chemical class C(C)(=O)* 0.000 claims abstract description 11
- 150000007857 hydrazones Chemical class 0.000 claims abstract description 11
- 239000003960 organic solvent Substances 0.000 claims abstract description 9
- 150000002463 imidates Chemical class 0.000 claims abstract description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 162
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 87
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 15
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 13
- 235000011181 potassium carbonates Nutrition 0.000 claims description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 11
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 125000006736 (C6-C20) aryl group Chemical group 0.000 claims description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 6
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 6
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 238000006053 organic reaction Methods 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 150000007514 bases Chemical class 0.000 claims description 4
- 125000004185 ester group Chemical group 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 4
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 4
- 239000011736 potassium bicarbonate Substances 0.000 claims description 4
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 4
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 4
- 235000011009 potassium phosphates Nutrition 0.000 claims description 4
- 239000001632 sodium acetate Substances 0.000 claims description 4
- 235000017281 sodium acetate Nutrition 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims description 2
- 229940086066 potassium hydrogencarbonate Drugs 0.000 claims description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 229940093916 potassium phosphate Drugs 0.000 claims 1
- 229960004249 sodium acetate Drugs 0.000 claims 1
- -1 fluoroalkyl diazo compounds Chemical class 0.000 abstract description 32
- 238000001228 spectrum Methods 0.000 abstract description 12
- 239000000463 material Substances 0.000 abstract description 5
- 239000000758 substrate Substances 0.000 abstract description 4
- 239000003054 catalyst Substances 0.000 abstract description 3
- 229910052751 metal Inorganic materials 0.000 abstract description 3
- 239000002184 metal Substances 0.000 abstract description 3
- 238000007363 ring formation reaction Methods 0.000 abstract description 3
- 239000002360 explosive Substances 0.000 abstract description 2
- 150000002894 organic compounds Chemical class 0.000 abstract description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 75
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 50
- 239000000047 product Substances 0.000 description 50
- 238000004809 thin layer chromatography Methods 0.000 description 50
- 239000002904 solvent Substances 0.000 description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 26
- 238000004440 column chromatography Methods 0.000 description 26
- 239000012074 organic phase Substances 0.000 description 26
- 239000012043 crude product Substances 0.000 description 25
- 239000003208 petroleum Substances 0.000 description 25
- 238000005406 washing Methods 0.000 description 25
- 238000001514 detection method Methods 0.000 description 24
- 238000004821 distillation Methods 0.000 description 24
- 239000003480 eluent Substances 0.000 description 24
- 238000000746 purification Methods 0.000 description 24
- 150000003839 salts Chemical class 0.000 description 23
- 238000003756 stirring Methods 0.000 description 19
- 239000007787 solid Substances 0.000 description 15
- 238000011068 loading method Methods 0.000 description 13
- 239000007788 liquid Substances 0.000 description 9
- LRLFBWUNBDVBGN-UHFFFAOYSA-N 1,5-diphenyl-3-(trifluoromethyl)-1,2,4-triazole Chemical compound C=1C=CC=CC=1N1N=C(C(F)(F)F)N=C1C1=CC=CC=C1 LRLFBWUNBDVBGN-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 6
- 229910052731 fluorine Inorganic materials 0.000 description 6
- 239000011737 fluorine Substances 0.000 description 6
- 150000002484 inorganic compounds Chemical class 0.000 description 6
- 229910010272 inorganic material Inorganic materials 0.000 description 6
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical class C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 5
- XAHIWQQBROYNOI-UHFFFAOYSA-N FC(C(N=C1C2=CC=CC=C2)=NN1C1=CC=CC=C1)F Chemical compound FC(C(N=C1C2=CC=CC=C2)=NN1C1=CC=CC=C1)F XAHIWQQBROYNOI-UHFFFAOYSA-N 0.000 description 4
- PTTFGXCABBGOEC-UHFFFAOYSA-N FC(C(N=C1C2CCCC2)=NN1C1=CC=CC=C1)(F)F Chemical compound FC(C(N=C1C2CCCC2)=NN1C1=CC=CC=C1)(F)F PTTFGXCABBGOEC-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- 229910017053 inorganic salt Inorganic materials 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 150000000178 1,2,4-triazoles Chemical class 0.000 description 2
- OSTCYBYGDHHNIQ-UHFFFAOYSA-N 5-(4-bromophenyl)-1-phenyl-3-(trifluoromethyl)-1,2,4-triazole Chemical compound C=1C=CC=CC=1N1N=C(C(F)(F)F)N=C1C1=CC=C(Br)C=C1 OSTCYBYGDHHNIQ-UHFFFAOYSA-N 0.000 description 2
- ZHLSCCVQHUIRSW-UHFFFAOYSA-N 5-naphthalen-2-yl-1-phenyl-3-(trifluoromethyl)-1,2,4-triazole Chemical compound C1=C(C=CC2=CC=CC=C12)C1=NC(=NN1C1=CC=CC=C1)C(F)(F)F ZHLSCCVQHUIRSW-UHFFFAOYSA-N 0.000 description 2
- ACLWPHNNLQKLEQ-UHFFFAOYSA-N FC(C(N=C1C2=CC=CC=C2)=NN1C1=CC2=CC=CC=C2C=C1)(F)F Chemical compound FC(C(N=C1C2=CC=CC=C2)=NN1C1=CC2=CC=CC=C2C=C1)(F)F ACLWPHNNLQKLEQ-UHFFFAOYSA-N 0.000 description 2
- OQDWJKBUYLRYDQ-UHFFFAOYSA-N FC(C(N=C1C2=CC=CS2)=NN1C1=CC=CC=C1)(F)F Chemical compound FC(C(N=C1C2=CC=CS2)=NN1C1=CC=CC=C1)(F)F OQDWJKBUYLRYDQ-UHFFFAOYSA-N 0.000 description 2
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- RHDYQUZYHZWTCI-UHFFFAOYSA-N 1-methoxy-4-phenylbenzene Chemical compound C1=CC(OC)=CC=C1C1=CC=CC=C1 RHDYQUZYHZWTCI-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- SZQUNAOZNFKTHM-UHFFFAOYSA-N 3-ethylpiperidine-2,6-dione Chemical compound CCC1CCC(=O)NC1=O SZQUNAOZNFKTHM-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- KBEBGUQPQBELIU-CMDGGOBGSA-N Ethyl cinnamate Chemical compound CCOC(=O)\C=C\C1=CC=CC=C1 KBEBGUQPQBELIU-CMDGGOBGSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- KBEBGUQPQBELIU-UHFFFAOYSA-N cinnamic acid ethyl ester Natural products CCOC(=O)C=CC1=CC=CC=C1 KBEBGUQPQBELIU-UHFFFAOYSA-N 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- FMSOAWSKCWYLBB-VBGLAJCLSA-N deferasirox Chemical compound C1=CC(C(=O)O)=CC=C1N(N\C(N\1)=C\2C(C=CC=C/2)=O)C/1=C\1C(=O)C=CC=C/1 FMSOAWSKCWYLBB-VBGLAJCLSA-N 0.000 description 1
- 229960001489 deferasirox Drugs 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 150000008049 diazo compounds Chemical class 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- DSHWMBCJDOGPTB-UHFFFAOYSA-N ethyl 2-ethoxy-2-iminoacetate Chemical compound CCOC(=N)C(=O)OCC DSHWMBCJDOGPTB-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- VQSRKMNBWMHJKY-YTEVENLXSA-N n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-methoxypyrazine-2-carboxamide Chemical compound C1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]23[C@@H](CN(C2)C=2N=CC(F)=CN=2)CSC(N)=N3)=C1 VQSRKMNBWMHJKY-YTEVENLXSA-N 0.000 description 1
- CSHYUNAVCFTOHX-UHFFFAOYSA-N n-ethyl-3-phenylprop-2-enamide Chemical compound CCNC(=O)C=CC1=CC=CC=C1 CSHYUNAVCFTOHX-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种1,5‑二取代‑3‑氟烷基‑1,2,4‑三氮唑化合物及其制备方法和应用,属于有机化合物制备技术领域。本发明将式(Ⅰ)所示的2‑氟烷基‑N‑取代乙酰卤代腙,与式(Ⅱ)所示的亚氨酸酯及碱性化合物在有机溶剂中混合,发生[3+2]环化反应,有效制备式(Ⅲ)所示的1,5‑二取代‑3‑氟烷基‑1,2,4‑三氮唑。本发明采用简单易得的2‑氟烷基‑N‑取代乙酰卤代腙合成砌块,避免使用易爆的氟烷基重氮类化合物,且不需要金属催化剂,操作步骤简单,反应条件温和,区域选择性好,收率高,底物谱广,所得化合物可广泛用于有机化学、材料化学和药物化学领域。
Description
技术领域
本发明属于有机化合物制备技术领域,具体涉及一种1,5-二取代-3-氟烷基-1,2,4-三氮唑化合物及其制备方法和应用。
背景技术
多取代1,2,4-三唑类化合物是在医药、生物、功能材料和配体化学等领域有着广泛的应用,尤其是3-或5-氟烷基取代的1,2,4-三氮唑骨架已成为许多药物分子和抑制剂的核心结构(Lu S N, Yang H, Zhang J, et al. Oxidative Cyclization ofTrifluoroacetimidohydrazides with D‐Glucose for the Metal‐Free Synthesis of3‐Trifluoromethyl‐1, 2, 4‐Triazoles[J]. Advanced Synthesis & Catalysis, 2021,363(21): 4982-4987. Tang J, Zhang J, Zhang Y, et al. Palladium-catalyzedcarbonylative synthesis of 5-trifluoromethyl-1, 2, 4-triazoles fromtrifluoroacetimidohydrazides and aryl iodides[J]. Organic ChemistryFrontiers, 2021, 8(21): 6089-6094.)。目前越来越多的化学家、药物学家和材料学家致力于开发此类氟烷基取代的1,2,4-三氮唑化合物的制备方法。
一方面,构建氟烷基取代的五元含氮杂环化合物的传统方法:主要是采用含氟烷基重氮类化合物作为1,3-偶极子与亲偶极子发生[3+2]环加成反应,但此类重氮化合物往往活性较高不易操作,具有潜在爆炸的风险,不利于工业生产,因此需要寻找更加友好的合成砌块来替代反应。另一方面,目前针对3-氟烷基取代的1,2,4-三氮唑的方法较少,而现有的方法往往存在诸多问题:如原料合成步骤繁琐、不易操作,使用金属催化剂、成本高,反应产率低、底物谱窄、区域选择性差和异构体分离困难等(Czollner L, Szilágyi G, LangóJ, et al. 1, 2, 4-Triazoles, II Synthesis of 1, 5-diphenyl-3-trifluoromethyl-1H-1, 2, 4-triazoles[J]. Monatshefte für Chemie/Chemical Monthly, 1988, 119(3): 349-353. Buscemi S, Pace A, Pibiri I, et al. Fluorinated heterocycliccompounds. An expedient route to 5-perfluoroalkyl-1, 2, 4-triazoles via anunusual hydrazinolysis of 5-perfluoroalkyl-1, 2, 4-oxadiazoles: Firstexamples of an ANRORC-like reaction in 1, 2, 4-oxadiazole derivatives[J]. TheJournal of Organic Chemistry, 2003, 68(2): 605-608. Buscemi S, Pace A,Piccionello A P, et al. Five-to-six membered ring-rearrangements in thereaction of 5-perfluoroalkyl-1, 2, 4-oxadiazoles with hydrazine andmethylhydrazine[J]. The Journal of Organic Chemistry, 2006, 71(21): 8106-8113. Peng X, Zhang F G, Ma J A. Cu‐Catalysed Three‐Component Reaction ofAryldiazonium Salts with Fluorinated Diazo Reagents and Nitriles: Access toDifluoro‐and Trifluoromethylated N1‐Aryl‐1, 2, 4‐triazoles[J]. AdvancedSynthesis & Catalysis, 2020, 362(20): 4432-4437. Liu X, Liu H, Bian C, et al.Synthesis of 3-Trifluoromethyl-1, 2, 4-triazolines and 1, 2, 4-Triazoles viaTandem Addition/Cyclization of Trifluoromethyl N-Acylhydrazones withCyanamide[J]. The Journal of Organic Chemistry, 2022, 87(9): 5882-5892.)。
因此,以安全易得的2-氟烷基-N-取代乙酰卤代腙作为氟烷基化砌块,发展一种高效简洁的1,5-二取代3-氟烷基-1,2,4-三氮唑制备方法具有重要的理论意义和应用价值,且向3-氟烷基-1,2,4-三氮唑中引入氰基、卤素、双键等官能团为后续多样性的衍生化奠定了基础。
发明内容
针对现有技术存在的上述问题,本发明所要解决的第一技术问题在于提供一种1,5-二取代-3-氟烷基-1,2,4-三氮唑化合物的制备方法;本发明所要解决的第二技术问题在于提供该方法制备得到的1,5-二取代-3-氟烷基-1,2,4-三氮唑化合物;本发明所要解决的第三技术问题在于提供1,5-二取代-3-氟烷基-1,2,4-三氮唑化合物的应用。
为了解决上述技术问题,本发明所采用的技术方案如下:
一种1,5-二取代-3-氟烷基-1,2,4-三氮唑化合物的制备方法,包括以下步骤:将式(Ⅰ)所示的2-氟烷基-N-取代乙酰卤代腙、式(Ⅱ)所示的取代亚氨酸酯、碱性化合物在有机溶剂中混合、反应,得到式(Ⅲ)所示的1,5-二取代-3-氟烷基-1,2,4-三氮唑;
其中,R1为取代或未取代的C6~C20的芳香基、取代或未取代的C5~C20的杂环基;所述取代或未取代的C6~C20的芳香基、取代或未取代的C5~C20的杂环基中的取代基选自C1~C5的烷基、C1~C5的烷氧基、C6~C14的芳基、C2~C24的不饱和烷基、含硫基团、氟烷基、卤素、氰基、硝基与酯基中的一种或多种;
Rf选自二氟甲基、三氟甲基或五氟乙基中的一种;
X选自氯、溴或碘中的一种;
R2为取代或未取代的C1~C6的直链烷基、取代或未取代的C3~C8的环烷基、取代或未取代的C6~C20的芳香基、取代或未取代的C5~C20的杂环基;所述取代或未取代的C1~C6的直链烷基、取代或未取代的C3~C8的环烷基、取代或未取代的C6~C20的芳香基、取代或未取代的C5~C20的杂环基中的取代基选自C1~C5的烷基、C1~C5的烷氧基、C6~C14的芳基、C2~C24的不饱和烷基、含硫基团、氟烷基、卤素、氰基、硝基与酯基中的一种或多种。
进一步的,所述碱性化合物选自碳酸钠、碳酸钾、碳酸铯、碳酸氢钠、碳酸氢钾、醋酸钠、磷酸钾、叔丁醇钾、三乙胺中的一种或多种。
进一步的,所述有机溶剂选自二氯甲烷、1,2-二氯乙烷、乙酸乙酯、四氢呋喃、乙醇、甲苯、乙腈、1,4-二氧六环、N,N-二甲基甲酰胺中的一种或多种。
进一步的,反应的温度为0~120℃。
进一步的,反应的时间为1~24h。
进一步的,2-氟烷基-N-取代乙酰卤代腙、取代亚氨酸酯和碱性化合物的摩尔比为1:(1~5):(1~10)。
进一步的,2-氟烷基-N-取代乙酰卤代腙与有机溶剂的用量比为0.4 mmol:2-4mL。
进一步的,将式(Ⅰ)所示的2-氟烷基-N-取代乙酰卤代腙、式(Ⅱ)所示的取代亚氨酸酯、碱性化合物在有机溶剂中混合、反应后,过滤除去反应体系中的无机盐,二氯甲烷洗涤滤渣,获得的有机相合并后减压蒸馏除去溶剂,采用以硅胶填充物的柱层析方法进行纯化,得到式(Ⅲ)所示的1,5-二取代-3-氟烷基-1,2,4-三氮唑。
进一步的,1,5-二取代-3-氟烷基-1,2,4-三氮唑化合物具有如下结构式中的一种:
所述的1,5-二取代-3-氟烷基-1,2,4-三氮唑化合物在制备含3-氟烷基-1,2,4-三氮唑骨架的药物中的应用。
所述的1,5-二取代-3-氟烷基-1,2,4-三氮唑化合物在作为配体参与有机反应中的应用。
相比于现有技术,本发明的有益效果为:
1)本发明首次采用式(Ⅰ)所示的2-氟烷基-N-取代乙酰卤代腙,与式(Ⅱ)所示的亚氨酸酯及碱性化合物在有机溶剂中混合,发生[3+2]环化反应,有效制备1,5-二取代-3-氟烷基-1,2,4-三氮唑,一方面,利用本发明所提供的方法可以制备含3-氟烷基-1,2,4-三氮唑骨架的药物类似物,具有可观的应用价值;另一方面,利用本发明提供的方法合成杂环、羰基取代的1,2,4-三氮唑可用作配体参与有机反应,在有机化学和材料化学领域具有应用价值。
2)与传统的含氟烷基重氮类化合物的[3+2]环加成反应相比,本发明提供的方法具有以下优点:原料合成步骤更加简单、易于操作,减少了潜在爆炸的风险,且不需要金属催化剂,反应条件温和、区域选择性好、收率高、底物谱广等。
附图说明
图1为实施例1所制备得到的1-苯基-5-苯基-3-二氟甲基-1,2,4-三氮唑的核磁氢谱图;
图2为实施例1所制备得到的1-苯基-5-苯基-3-二氟甲基-1,2,4-三氮唑的氟谱图;
图3为实施例6所制备得到的1,5-二苯基-3-三氟甲基-1,2,4-三氮唑的核磁氢谱图;
图4为实施例6所制备得到的1,5-二苯基-3-三氟甲基-1,2,4-三氮唑的氟谱图;
图5为实施例7所制备得到的5-苯基-1-(4-甲基)苯基-3-三氟甲基-1,2,4-三氮唑的核磁氢谱图;
图6为实施例7所制备得到的5-苯基-1-(4-甲基)苯基-3-三氟甲基-1,2,4-三氮唑的氟谱图;
图7为实施例20所制备得到的5-环戊基-1-苯基-3-三氟甲基-1,2,4-三氮唑的核磁氢谱图;
图8为实施例20所制备得到的5-环戊基-1-苯基-3-三氟甲基-1,2,4-三氮唑的氟谱图。
具体实施方式
下面结合具体实施例对本发明进一步进行描述。这些实施例仅用于说明本发明而不用于限制本发明的范围。在不背离本发明精神和实质的情况下,对本发明方法、步骤或条件所作的修改或替换,均属于本发明的范围。以下实施例中如无特殊说明,实施例中所用的技术手段均为本领域技术人员所熟知的常规手段。
实施例1:1-苯基-5-苯基-3-二氟甲基-1,2,4-三氮唑的制备(化合物1)
制备方法:在干燥的25 mL史莱克(Schlenk)装置中,称入碳酸钾(110.6 mg, 0.8mmol),2-二氟甲基-N-苯基乙酰氯代腙(81.8 mg, 0.4 mmol),苯基亚氨酸酯(89.5 mg,0.6 mmol),随后向体系中加入1,4-二氧六环溶液(3 mL),80 ℃下搅拌5小时。薄层色谱法(TLC)检测反应完全后,硅藻土过滤除去体系中的无机盐,二氯甲烷洗涤滤渣,有机相合并,减压蒸馏除去溶剂,粗品溶于0.5 mL二氯甲烷后上样,柱层析纯化(洗脱液:石油醚/乙酸乙酯 = 200:1~80:1)可得到目标产物1-苯基-5苯基-3-二氟甲基-1,2,4-三氮唑,浅黄色固体82.9 mg,产率95%。
核磁共振检测产物结构,数据如下:
1H NMR (400 MHz, CDCl3) δ 7.52 – 7.50 (m, 2H), 7.48 – 7.41 (m, 4H),7.40 – 7.32 (m, 4H), 6.81 (t, J = 53.6 Hz, 1H);
19F NMR (376 MHz, CDCl3) δ -116.87 (d, J = 53.6 Hz)。
实施例2:1-(2-甲氧基)苯基-5-苄基-3-二氟甲基-1,2,4-三氮唑的制备(化合物2)
制备方法:在干燥的25 mL史莱克(Schlenk)装置中,称入磷酸钾(679.3 mg, 3.2mmol),2-二氟甲基-N-(2-甲氧基)苯基乙酰氯代腙(93.8 mg, 0.4 mmol),苄基亚氨酸酯(326.5 mg, 2.0 mmol),随后向体系中加入无水乙醇溶液(4 mL),25 ℃下搅拌18小时。薄层色谱法(TLC)检测反应完全后,硅藻土过滤除去体系中的无机盐,二氯甲烷洗涤滤渣,有机相合并,减压蒸馏除去溶剂,粗品溶于0.5 mL二氯甲烷后上样,柱层析纯化(洗脱液:石油醚/乙酸乙酯 = 200:1~90:1)可得到目标产物1-(2-甲氧基)苯基-5-苄基-3-二氟甲基-1,2,4-三氮唑,浅黄色油状物117.3 mg,产率93%。
核磁共振检测产物结构,数据如下:
1H NMR (400 MHz, CDCl3) δ 7.61–7.59 (m, 1H), 7.39–7.36 (m, 1H), 7.28–7.20 (m, 6H), 7.00–6.99 (m, 1H), 6.44 (t, J = 53.9 Hz, 1H),4.01 (s, 1H), 3.95(s, 1H);
19F NMR (376 MHz, CDCl3) δ -116.8 (d, J = 53.9 Hz)。
实施例3:1-(1-吡啶基)-5-环丙基-3-二氟甲基-1,2,4-三氮唑的制备(化合物3)
制备方法:在干燥的25 mL史莱克(Schlenk)装置中,称入碳酸氢钠(504.6 mg,2.4 mmol),2-二氟甲基-N-(2-吡啶基)乙酰氯代腙(89.4 mg, 0.4 mmol),环丙基亚氨酸酯(135.8 mg, 1.2 mmol),随后向体系中加入N,N-二甲基甲酰胺溶液(3 mL),120 ℃下搅拌1小时。薄层色谱法(TLC)检测反应完全后,硅藻土过滤除去体系中的无机盐,二氯甲烷洗涤滤渣,有机相合并,减压蒸馏除去溶剂,粗品溶于0.5 mL二氯甲烷后上样,柱层析纯化(洗脱液:石油醚/乙酸乙酯 = 100:1~50:1)可得到目标产物1-(1-吡啶基)-5-环丙基-3-二氟甲基-1,2,4-三氮唑,浅黄色液体85.0 mg,产率90%。
核磁共振检测产物结构,数据如下:
1H NMR (400 MHz, CDCl3) δ 8.52–8.51 (m, 1H), 8.33 (s, 1H), 7.73–7.70(m, 1H), 7.35–7.31 (m, 1H), 6.41 (t, J = 53.8 Hz, 1H),2.25 (m, 1H), 1.24 (m,4H);
19F NMR (376 MHz, CDCl3) δ -113.2 (d, J = 53.7 Hz)。
实施例4:3-二氟甲基-5-己烷基-1,2,4-三氮唑的制备(化合物4)
制备方法:在干燥的25 mL史莱克(Schlenk)装置中,称入碳酸铯(260.7 mg, 0.8mmol),2-二氟甲基-N-苯基乙酰氯代腙(81.8 mg, 0.4 mmol),己基亚氨酸酯(191.1 mg,1.2 mmol),随后向体系中加入乙酸乙酯溶液(2.5 mL),0 ℃下搅拌24小时。薄层色谱法(TLC)检测反应完全后,硅藻土过滤除去体系中的无机盐,二氯甲烷洗涤滤渣,有机相合并,减压蒸馏除去溶剂,粗品溶于0.5 mL二氯甲烷后上样,柱层析纯化(洗脱液:石油醚/乙酸乙酯 = 200:1~150:1)可得到目标产物3-二氟甲基-5-己烷基-1,2,4-三氮唑,黄色液体108.0mg,产率96%。
核磁共振检测产物结构,数据如下:
1H NMR (400 MHz, CDCl3) δ 7.67–7.52 (m, 2H), 7.50–7.47 (m, 3H), 6.35(t, J = 54.1 Hz, 1H),2.85–2.83 (m, 4H), 2.76–2.74 (m, 6H), 2.64 (m, 3H);
19F NMR (376 MHz, CDCl3) δ -115.3 (d, J = 53.8 Hz)。
实施例5:5-(2-氯苯基)-3-二氟甲基-1-苯基-1,2,4-三氮唑的制备(化合物5)
制备方法:在干燥的25 mL史莱克(Schlenk)装置中,称入碳酸氢钾(360.3 mg,3.6 mmol),2-二氟甲基-N-苯基乙酰氯代腙(81.8 mg, 0.4 mmol),2-氯苯基亚氨酸酯(293.8 mg, 1.6 mmol),随后向体系中加入乙腈溶液(2 mL),60 ℃下搅拌2小时。薄层色谱法(TLC)检测反应完全后,硅藻土过滤除去体系中的无机盐,二氯甲烷洗涤滤渣,有机相合并,减压蒸馏除去溶剂,粗品溶于0.5 mL二氯甲烷后上样,柱层析纯化(洗脱液:石油醚/乙酸乙酯 = 100:1~50:1)可得到目标产物5-(2-氯苯基)-3-二氟甲基-1-苯基-1,2,4-三氮唑,浅黄色固体116.1 mg,产率95%。
核磁共振检测产物结构,数据如下:
1H NMR (400 MHz, CDCl3) δ 8.24–8.21 (m, 2H), 7.73 (s, 1H), 7.63–7.50(m, 4H), 7.38–7.35 (m, 2H), 6.37 (t, J = 53.7 Hz, 1H);
19F NMR (376 MHz, CDCl3) δ -115.7 (d, J = 53.9 Hz)。
实施例6:1,5-二苯基-3-三氟甲基-1,2,4-三氮唑的制备(化合物6)
制备方法:在干燥的25 mL史莱克(Schlenk)装置中,称入碳酸钾(110.6 mg, 0.8mmol),2-三氟甲基-N-苯基乙酰氯代腙(89.0 mg, 0.4 mmol),苯基亚氨酸酯(89.5 mg,0.6mmol),随后向体系中加入1,2-二氯乙烷溶液(3 mL),80 ℃下搅拌3小时。薄层色谱法(TLC)检测反应完全后,硅藻土过滤除去体系中的无机盐,二氯甲烷洗涤滤渣,有机相合并,减压蒸馏除去溶剂,粗品溶于0.5mL二氯甲烷后上样,柱层析纯化(洗脱液:石油醚/乙酸乙酯=200:1~100:1)可得到目标产物1,5-二苯基-3-三氟甲基-1,2,4-三氮唑,黄色固体83.6mg,产率96%。
核磁共振检测产物结构,数据如下:
1H NMR (400 MHz, CDCl3) δ 7.53 – 7.47 (m, 4H), 7.47 – 7.42 (m, 2H),7.40 – 7.33 (m, 4H);
19F NMR (376 MHz, CDCl3) δ -65.29 (s)。
实施例7:5-苯基-1-(4-甲基)苯基-3-三氟甲基-1,2,4-三氮唑的制备(化合物7)
制备方法:在干燥的25 mL史莱克(Schlenk)装置中,称入碳酸钾(110.6 mg, 0.8mmol),2-三氟甲基-N-(4-甲基)苯基乙酰氯代腙(94.6 mg, 0.4 mmol),苯基亚氨酸酯(89.5 mg, 0.6mmol),随后向体系中加入1,2-二氯乙烷溶液(3 mL),80 ℃下搅拌3小时。薄层色谱法(TLC)检测反应完全后,硅藻土过滤除去体系中的无机盐,二氯甲烷洗涤滤渣,有机相合并,减压蒸馏除去溶剂,粗品溶于0.5mL二氯甲烷后上样,柱层析纯化(洗脱液:石油醚/乙酸乙酯=200:1~100:1)可得到目标产物5-苯基-1-(4-甲基)苯基-3-三氟甲基-1,2,4-三氮唑,黄色固体116.4 mg,产率95%。
核磁共振检测产物结构,数据如下:
1H NMR (400 MHz, CDCl3) δ 7.53 – 7.51 (m, 2H), 7.46 – 7.42 (m, 1H),7.36 (t, J = 7.5 Hz, 2H), 7.26 (s, 4H), 2.42 (s, 3H).;
19F NMR (376 MHz, CDCl3) δ -65.28 (s)。
实施例8:5-苯基-1-(4-甲氧基)苯基-3-三氟甲基-1,2,4-三氮唑的制备(化合物8)
制备方法:在干燥的25 mL史莱克(Schlenk)装置中,称入碳酸钾(165.9 mg, 1.2mmol),2-三氟甲基-N-(4-甲氧基)苯基乙酰氯代腙(101.0 mg, 0.4 mmol),苯基亚氨酸酯(89.5 mg, 0.6mmol),随后向体系中加入1,2-二氯乙烷溶液(3 mL),25 ℃下搅拌20小时。薄层色谱法(TLC)检测反应完全后,硅藻土过滤除去体系中的无机盐,二氯甲烷洗涤滤渣,有机相合并,减压蒸馏除去溶剂,粗品溶于0.5mL二氯甲烷后上样,柱层析纯化(洗脱液:石油醚/乙酸乙酯=200:1~100:1)可得到目标产物5-苯基-1-(4-甲氧基)苯基-3-三氟甲基-1,2,4-三氮唑,深褐色固体112.4mg,产率88%。
核磁共振检测产物结构,数据如下:
1H NMR (400 MHz, CDCl3) δ 7.55 – 7.49 (m, 2H), 7.44 (t, J = 7.4 Hz,1H), 7.36 (t, J = 7.5 Hz, 2H), 7.32 – 7.27 (m, 2H), 6.97 – 6.94 (m, 2H), 3.86(s, 3H);
19F NMR (377 MHz, CDCl3) δ -65.26 (s)。
实施例9:5-苯基-1-(4-氯)苯基-3-三氟甲基-1,2,4-三氮唑的制备(化合物9)
制备方法:在干燥的25 mL史莱克(Schlenk)装置中,称入碳酸铯(260.7 mg, 0.8mmol),2-三氟甲基-N-(4-氯)苯基乙酰氯代腙(102.8 mg, 0.4 mmol),苯基亚氨酸酯(179.0 mg, 1.2 mmol),随后向体系中加入1,4-二氧六环溶液(3 mL),100 ℃下搅拌2小时。薄层色谱法(TLC)检测反应完全后,硅藻土过滤除去体系中的无机盐,二氯甲烷洗涤滤渣,有机相合并,减压蒸馏除去溶剂,粗品溶于0.5mL二氯甲烷后上样,柱层析纯化(洗脱液:石油醚/乙酸乙酯=100:1~80:1)可得到目标产物5-苯基-1-(4-氯)苯基-3-三氟甲基-1,2,4-三氮唑,黄色固体121.1mg,产率94%。
核磁共振检测产物结构,数据如下:
1H NMR (400 MHz, CDCl3) δ 7.52 – 7.50 (m, 2H), 7.48 – 7.43 (m, 3H),7.41 – 7.37 (m, 2H), 7.35 – 7.33 (m, 2H);
19F NMR (376 MHz, CDCl3) δ -65.38 (s)。
实施例10:5-苯基-1-(4-氰基)苯基-3-三氟甲基-1,2,4-三氮唑的制备(化合物10)
制备方法:在干燥的25 mL史莱克(Schlenk)装置中,称入醋酸钾(196.3 mg, 2.0mmol),2-三氟甲基-N-(4-氰基)苯基乙酰氯代腙(99.0 mg, 0.4 mmol),苯基亚氨酸酯(89.5 mg, 0.6 mmol),随后向体系中加入乙腈溶液(2 mL),40 ℃下搅拌12小时。薄层色谱法(TLC)检测反应完全后,硅藻土过滤除去体系中的无机盐,二氯甲烷洗涤滤渣,有机相合并,减压蒸馏除去溶剂,粗品溶于0.5mL二氯甲烷后上样,柱层析纯化(洗脱液:石油醚/乙酸乙酯=150:1~100:1)可得到目标产物5-苯基-1-(4-氰基)苯基-3-三氟甲基-1,2,4-三氮唑,浅黄色液体119.2mg,产率95%。
核磁共振检测产物结构,数据如下:
1H NMR (400 MHz, CDCl3) δ 7.76 – 7.74 (m, 2H), 7.55 – 7.52 (m, 3H),7.50 – 7.48 (m, 2H), 7.42 (t, J = 7.5 Hz, 2H);
19F NMR (376 MHz, CDCl3) δ -65.47 (s)。
实施例11:1-(2-萘基)-5-苯基-3-三氟甲基-1,2,4-三氮唑的制备(化合物11)
制备方法:在干燥的25 mL史莱克(Schlenk)装置中,称入碳酸钠(169.6 mg, 1.6mmol),2-三氟甲基-N-(2-萘基)乙酰氯代腙(109.1 mg, 0.4 mmol),苯基亚氨酸酯(89.5mg, 0.6mmol),随后向体系中加入四氢呋喃溶液(3 mL),50 ℃下搅拌10小时。薄层色谱法(TLC)检测反应完全后,硅藻土过滤除去体系中的无机盐,二氯甲烷洗涤滤渣,有机相合并,减压蒸馏除去溶剂,粗品溶于0.5mL二氯甲烷后上样,柱层析纯化(洗脱液:石油醚/乙酸乙酯=150:1~100:1)可得到目标产物1-(2-萘基)-5-苯基-3-三氟甲基-1,2,4-三氮唑,黄色固体123.2mg,产率91%。
核磁共振检测产物结构,数据如下:
1H NMR (400 MHz, CDCl3) δ 7.95 (d, J = 1.8 Hz, 1H), 7.91 (d, J = 8.7Hz, 2H), 7.86 – 7.82 (m, 1H), 7.63 – 7.57 (m, 2H), 7.57 – 7.52 (m, 2H), 7.46– 7.38 (m, 2H), 7.34 (t, J = 7.6 Hz, 2H);
19F NMR (376 MHz, CDCl3) δ -65.23 (s)。
实施例12:1-(1-噻吩基)-5-苯基-3-三氟甲基-1,2,4-三氮唑的制备(化合物12)
制备方法:在干燥的25 mL史莱克(Schlenk)装置中,称入磷酸钾(509.4 mg, 2.4mmol),2-三氟甲基-N-(1-噻吩基)乙酰氯代腙(91.4 mg, 0.4 mmol),苯基亚氨酸酯(119.3mg, 0.8 mmol),随后向体系中加入二氯甲烷溶液(4 mL),0 ℃下搅拌15小时。薄层色谱法(TLC)检测反应完全后,硅藻土过滤除去体系中的无机盐,二氯甲烷洗涤滤渣,有机相合并,减压蒸馏除去溶剂,粗品溶于0.5mL二氯甲烷后上样,柱层析纯化(洗脱液:石油醚/乙酸乙酯=150:1~100:1)可得到目标产物1-(1-噻吩基)-5-苯基-3-三氟甲基-1,2,4-三氮唑,棕色固体117.6mg,产率99%。
核磁共振检测产物结构,数据如下:
1H NMR (400 MHz, CDCl3) δ 7.64 – 7.56 (m, 3H), 7.52 – 7.44 (m, 3H),7.15 (d, J = 3.0 Hz, 1H), 6.99 (dd, J = 4.9, 4.0 Hz, 1H);
19F NMR (376 MHz, CDCl3) δ -65.30 (s)。
实施例13:1-(苯并[d][1,3]二恶英-5-基)-5-苯基-3-(三氟甲基)-1,2,4-三氮唑的制备(化合物13)
制备方法:在干燥的25 mL史莱克(Schlenk)装置中,称入碳酸铯(260.6 mg, 0.8mmol),2-三氟甲基-N-(苯并[d][1,3]二恶英-5-基)乙酰溴代腙(124.4 mg, 0.4 mmol),苯基亚氨酸酯(89.5 mg, 0.6mmol),随后向体系中加入1,2-二氯乙烷溶液(3 mL),60 ℃下搅拌5小时。薄层色谱法(TLC)检测反应完全后,硅藻土过滤除去体系中的无机盐,二氯甲烷洗涤滤渣,有机相合并,减压蒸馏除去溶剂,粗品溶于0.5mL二氯甲烷后上样,柱层析纯化(洗脱液:石油醚/乙酸乙酯=150:1~100:1)可得到目标产物1-(苯并[d][1,3]二恶英-5-基)-5-苯基-3-(三氟甲基)-1,2,4-三氮唑,棕色固体130.6mg,产率98%。
核磁共振检测产物结构,数据如下:
1H NMR (400 MHz, CDCl3) δ 7.51 – 7.46 (m, 3H), 7.40 (dt, J = 7.8, 4.1Hz, 2H), 7.02 (dd, J = 8.1, 1.7 Hz, 1H), 6.97 (d, J = 1.6 Hz, 1H), 6.76 (d, J= 8.1 Hz, 1H), 6.00 (s, 2H);
19F NMR (376 MHz, CDCl3) δ -65.37 (s)。
实施例14:1-(1-呋喃基)-5-苯基-3-三氟甲基-1,2,4-三氮唑的制备(化合物14)
制备方法:在干燥的25 mL史莱克(Schlenk)装置中,称入碳酸钾(221.2 mg, 1.6mmol),2-三氟甲基-N-(1-呋喃基)乙酰氯代腙(85.0 mg, 0.4 mmol),苯基亚氨酸酯(89.5g, 0.6mmol),随后向体系中加入无水乙醇溶液(3 mL),70 ℃下搅拌2小时。薄层色谱法(TLC)检测反应完全后,硅藻土过滤除去体系中的无机盐,二氯甲烷洗涤滤渣,有机相合并,减压蒸馏除去溶剂,粗品溶于0.5mL二氯甲烷后上样,柱层析纯化(洗脱液:石油醚/乙酸乙酯=100:1~80:1)可得到目标产物1-(1-呋喃基)-5-苯基-3-三氟甲基-1,2,4-三氮唑,黄色固体107.1mg,产率96%。
核磁共振检测产物结构,数据如下:
1H NMR (400 MHz, CDCl3) δ 7.57 – 7.52 (m, 3H), 7.48 – 7.46 (m, 3H),6.61 (d, J = 3.5 Hz, 1H), 6.44 (dd, J = 3.5, 1.7 Hz, 1H);
19F NMR (376 MHz, CDCl3) δ -65.33 (s)。
实施例15:4-(5-苯基-3-(三氟甲基)-1H-1,2,4-三唑-1-基)吡啶的制备(化合物15)
制备方法:在干燥的25 mL史莱克(Schlenk)装置中,称入醋酸钠(196.8 mg, 2.4mmol),2-三氟甲基-N-(4-吡啶基)乙酰氯代腙(89.4 mg, 0.4 mmol),苯基亚氨酸酯(119.3mg, 0.8mmol),随后向体系中加入N,N-二甲基甲酰胺溶液(3 mL),100 ℃下搅拌8小时。薄层色谱法(TLC)检测反应完全后,硅藻土过滤除去体系中的无机盐,二氯甲烷洗涤滤渣,有机相合并,减压蒸馏除去溶剂,粗品溶于0.5mL二氯甲烷后上样,柱层析纯化(洗脱液:石油醚/乙酸乙酯=100:1~80:1)可得到目标产物1-(1-呋喃基)-5-苯基-3-三氟甲基-1,2,4-三氮唑,黄色固体104.5mg,产率90%。
核磁共振检测产物结构,数据如下:
1H NMR (400 MHz, CDCl3) δ 7.6 – 7.51(m, 3H), 7.48 7.41(m, 2H), 7.40(s, 1H), 7.37– 7.33(m, 3H);
19F NMR (376 MHz, CDCl3) δ -65.31 (s)。
实施例16:5-(2-萘基)-1-苯基-3-(三氟甲基)-1,2,4-三氮唑的制备(化合物16)
制备方法:在干燥的25 mL史莱克(Schlenk)装置中,称入碳酸钾(110.6 mg, 0.8mmol),2-三氟甲基-N-苯基乙酰氯代腙(89.0 mg, 0.4 mmol),2-萘基亚氨酸酯(119.6 mg,0.6mmol),随后向体系中加入1,2-二氯乙烷溶液(3 mL),80 ℃下搅拌4小时。薄层色谱法(TLC)检测反应完全后,硅藻土过滤除去体系中的无机盐,二氯甲烷洗涤滤渣,有机相合并,减压蒸馏除去溶剂,粗品溶于0.5mL二氯甲烷后上样,柱层析纯化(洗脱液:石油醚/乙酸乙酯=150:1~100:1)可得到目标产物5-(2-萘基)-1-苯基-3-(三氟甲基)-1,2,4-三氮唑,黄色固体130.3mg,产率96%。
核磁共振检测产物结构,数据如下:
1H NMR (400 MHz, CDCl3) δ 8.13 (s, 1H), 7.83 (d, J = 8.0 Hz, 1H), 7.78(t, J = 7.3 Hz, 2H), 7.57 (dd, J = 6.8, 0.9 Hz, 1H), 7.54 (dd, J = 3.6, 1.4Hz, 1H), 7.51 – 7.46 (m, 4H), 7.45 – 7.41 (m, 2H);
19F NMR (376 MHz, CDCl3) δ -65.20 (s)。
实施例17:5-丁基-1-苯基-3-(三氟甲基)-1H-1,2,4-三氮唑的制备(化合物17)
制备方法:在干燥的25 mL史莱克(Schlenk)装置中,称入碳酸钾(276.5 mg, 2.0mmol),2-三氟甲基-N-苯基乙酰氯代腙(89.0 mg, 0.4 mmol),戊酰亚胺乙酯(259.2 mg,2.0 mmol),随后向体系中加入1,4-二氧六环溶液(3 mL),100 ℃下搅拌1小时。薄层色谱法(TLC)检测反应完全后,硅藻土过滤除去体系中的无机盐,二氯甲烷洗涤滤渣,有机相合并,减压蒸馏除去溶剂,粗品溶于0.5mL二氯甲烷后上样,柱层析纯化(洗脱液:石油醚/乙酸乙酯=200:1~100:1)可得到目标产物5-丁基-1-苯基-3-(三氟甲基)-1H-1,2,4-三氮唑,棕色液体94.5mg,产率88%。
核磁共振检测产物结构,数据如下:
1H NMR (400 MHz, CDCl3) δ 7.57 – 7.49 (m, 3H), 7.46 – 7.39 (m, 2H),2.83 – 2.77 (m, 2H), 1.74 (dt, J = 15.4, 7.6 Hz, 2H), 1.39 – 1.27 (m, 2H),0.87 (t, J = 7.4 Hz, 3H);
19F NMR (376 MHz, CDCl3) δ -65.33 (s)。
实施例18:5-(4-溴苯基)-1-苯基-3-(三氟甲基)-1,2,4-三氮唑的制备(化合物18)
制备方法:在干燥的25 mL史莱克(Schlenk)装置中,称入三乙胺(323.8 mg, 3.2mmol),2-三氟甲基-N-苯基乙酰氯代腙(89.0 mg, 0.4 mmol),4-溴苯基亚胺酸酯(136.9mg, 0.6 mmol),随后向体系中加入1,2-二氯乙烷溶液(3 mL),80 ℃下搅拌3小时。薄层色谱法(TLC)检测反应完全后,硅藻土过滤除去体系中的无机盐,二氯甲烷洗涤滤渣,有机相合并,减压蒸馏除去溶剂,粗品溶于0.5mL二氯甲烷后上样,柱层析纯化(洗脱液:石油醚/乙酸乙酯=200:1~100:1)可得到目标产物5-(4-溴苯基)-1-苯基-3-(三氟甲基)-1,2,4-三氮唑,棕色液体143.5mg,产率97%。
核磁共振检测产物结构,数据如下:
1H NMR (400 MHz, CDCl3) δ 7.53 – 7.50 (m, 3H), 7.49 – 7.44 (m, 2H),7.40 (s, 1H), 7.39 – 7.35 (m, 3H);
19F NMR (376 MHz, CDCl3) δ -65.31 (s)。
实施例19:1-苯基-5-(2-噻吩基)-3-三氟甲基-1,2,4-三氮唑的制备(化合物19)
制备方法:在干燥的25 mL史莱克(Schlenk)装置中,称入碳酸钾(110.6 mg, 0.8mmol),2-三氟甲基-N-苯基乙酰氯代腙(89.0 mg, 0.4 mmol),2-噻吩基亚胺酸酯(93.2mg, 0.6 mmol),随后向体系中加入1,2-二氯乙烷溶液(3 mL),60 ℃下搅拌8小时。薄层色谱法(TLC)检测反应完全后,硅藻土过滤除去体系中的无机盐,二氯甲烷洗涤滤渣,有机相合并,减压蒸馏除去溶剂,粗品溶于0.5mL二氯甲烷后上样,柱层析纯化(洗脱液:石油醚/乙酸乙酯=200:1~100:1)可得到目标产物1-苯基-5-(2-噻吩基)-3-三氟甲基-1,2,4-三氮唑,棕色液体116.0 mg,产率98%。
核磁共振检测产物结构,数据如下:
1H NMR (400 MHz, CDCl3) δ 7.62 – 7.54 (m, 3H), 7.50 – 7.42 (m, 3H),7.13 (d, J = 3.0 Hz, 1H), 6.97 (dd, J = 4.9, 4.0 Hz, 1H);
19F NMR (376 MHz, CDCl3) δ -65.30 (s)。
实施例20:5-环戊基-1-苯基-3-三氟甲基-1,2,4-三氮唑的制备(化合物20)
制备方法:在干燥的25 mL史莱克(Schlenk)装置中,称入碳酸钾(110.6 mg, 0.8mmol),2-三氟甲基-N-苯基乙酰氯代腙(89.0 mg, 0.4 mmol),环戊基亚胺酸酯(84.7 mg,0.6 mmol),随后向体系中加入1,2-二氯乙烷溶液(3 mL),80 ℃下搅拌4小时。薄层色谱法(TLC)检测反应完全后,硅藻土过滤除去体系中的无机盐,二氯甲烷洗涤滤渣,有机相合并,减压蒸馏除去溶剂,粗品溶于0.5mL二氯甲烷后上样,柱层析纯化(洗脱液:石油醚/乙酸乙酯=150:1~100:1)可得到目标产物5-环戊基-1-苯基-3-三氟甲基-1,2,4-三氮唑,黄色液体106.9 mg,产率96%。
核磁共振检测产物结构,数据如下:
1H NMR (400 MHz, CDCl3) δ 7.57 – 7.53 (m, 3H), 7.45 – 7.40 (m, 2H),3.18 – 3.09 (m, 1H), 2.00 – 1.92 (m, 4H), 1.91 – 1.83 (m, 2H), 1.65 – 1.59(m, 2H);
19F NMR (376 MHz, CDCl3) δ -65.24 (s)。
实施例21:5-苯基-1-苯基-3-五氟乙基-1,2,4-三氮唑的制备(化合物21)
制备方法:在干燥的25 mL史莱克(Schlenk)装置中,称入碳酸铯(260.6 mg, 0.8mmol),2-五氟乙基-N-(苯基乙酰氯代腙(110.0 mg, 0.4 mmol),苯基亚氨酸酯(89.5 mg,0.6 mmol),随后向体系中加入1,4-二氧六环溶液(4 mL),60 ℃下搅拌12小时。薄层色谱法(TLC)检测反应完全后,硅藻土过滤除去体系中的无机盐,二氯甲烷洗涤滤渣,有机相合并,减压蒸馏除去溶剂,粗品溶于0.5 mL二氯甲烷后上样,柱层析纯化(洗脱液:石油醚/乙酸乙酯 = 200:1~100:1)可得到目标产物5-苯基-1-苯基-3-五氟乙基-1,2,4-三氮唑,黄色固体122.5 mg,产率89%。
核磁共振检测产物结构,数据如下:
1H NMR (400 MHz, CDCl3) δ 8.48–8.39 (m, 2H), 7.92–7.86 (m, 3H), 7.54–7.50 (m, 5H);
19F NMR (376 MHz, CDCl3) δ -85.31 (t, J = 2.7 Hz),-115.91(s)。
实施例22:(E)-2-(3-(五氟乙基)-5-苯乙烯基-1,2,4-三唑-1-基)吡啶的制备(化合物22)
制备方法:在干燥的25 mL史莱克(Schlenk)装置中,称入碳酸钾(221.2 mg, 1.6mmol),2-三氟甲基-N-4-吡啶基乙酰氯代腙(109.4 mg, 0.4 mmol),肉桂酸乙酯(140.2mg, 0.8 mmol),随后向体系中加入1,2-二氯乙烷溶液(3 mL),80 ℃下搅拌3小时。薄层色谱法(TLC)检测反应完全后,硅藻土过滤除去体系中的无机盐,二氯甲烷洗涤滤渣,有机相合并,减压蒸馏除去溶剂,粗品溶于0.5 mL二氯甲烷后上样,柱层析纯化(洗脱液:石油醚/乙酸乙酯 = 150:1~100:1)可得到目标产物(E)-2-(3-(五氟乙基)-5-苯乙烯基-1,2,4-三唑-1-基)吡啶,黄色固体133.2 mg,产率91%。
核磁共振检测产物结构,数据如下:
1H NMR (400 MHz, CDCl3) δ 8.48–8.42 (m, 2H), 7.66–7.61 (m, 2H), 7.40–7.33 (m, 5H),6.99 (d, J = 16.0 Hz, 1H), 6.95 (d, J = 16.0 Hz, 1H);
19F NMR (376 MHz, CDCl3) δ -84.91 (t, J = 2.4 Hz), -113.99 (s)。
实施例23:1-苯基-3-五氟乙基-5-苯乙炔基-1,2,4-三氮唑的制备(化合物23)
制备方法:在干燥的25 mL史莱克(Schlenk)装置中,称入碳酸氢钾(80.1 mg, 0.8mmol),(Z)-N-苯基-2-五氟乙基乙酰氯代腙(120.2 mg, 0.4 mmol),3-苯基丙烯酰胺乙酯(103.9 mg, 0.6 mmol),随后向体系中加入N,N-二甲基甲酰胺溶液(3 mL),120 ℃下搅拌1小时。薄层色谱法(TLC)检测反应完全后,硅藻土过滤除去体系中的无机盐,二氯甲烷洗涤滤渣,有机相合并,减压蒸馏除去溶剂,粗品溶于0.5 mL二氯甲烷后上样,柱层析纯化(洗脱液:石油醚/乙酸乙酯 = 200:1~100:1)可得到目标产物1-苯基-3-五氟乙基-5-苯乙炔基-1,2,4-三氮唑,棕色液体130.8 mg,产率90%。
核磁共振检测产物结构,数据如下:
1H NMR (400 MHz, CDCl3) δ 7.80–7.74 (m,2H), 7.72–7.62 (m,2H), 7.58–7.54 (m, 3H), 7.46–7.44 (m, 3H);
19F NMR (376 MHz, CDCl3) δ -84.31 (t, J = 2.6 Hz),-113.94 (s)。
实施例24:1-(呋喃-2-基)-3-(五氟乙基)-1,2,4-三氮唑-5-羧酸乙酯的制备(化合物24)
制备方法:在干燥的25 mL史莱克(Schlenk)装置中,称入醋酸钠(163.3 mg, 1.2mmol),(Z)-2-五氟乙基-N-(呋喃-2-基)丙酮腙酰氯(105.0 mg, 0.4 mmol),2-乙氧基-2-亚氨基乙酸乙酯(174.2 mg, 1.2 mmol),随后向体系中加入甲苯溶液(3 mL),90 ℃下搅拌15小时。薄层色谱法(TLC)检测反应完全后,硅藻土过滤除去体系中的无机盐,二氯甲烷洗涤滤渣,有机相合并,减压蒸馏除去溶剂,粗品溶于0.5 mL二氯甲烷后上样,柱层析纯化(洗脱液:石油醚/乙酸乙酯 = 200:1~150:1)可得到目标产物1-(呋喃-2-基)-3-(五氟乙基)-1,2,4-三氮唑-5-羧酸乙酯,黄色液体115.8 mg,产率89%。
核磁共振检测产物结构,数据如下:
1H NMR (400 MHz, CDCl3) δ 7.88–7.84 (m, 1H), 6.51–6.49 (m, 2H), 4.55(q, J = 7.0 Hz, 2H), 1.36 (t, J = 7.0 Hz, 3H);
19F NMR (376 MHz, CDCl3) δ -85.52 (t, J = 2.6 Hz),-114.68 (s)。
实施例25:(1-(4-溴吡啶-2-基)-3-(五氟乙基)-1,2,4-三唑-5-基)(苯基)甲酮的制备(化合物25)
制备方法:在干燥的25 mL史莱克(Schlenk)装置中,称入碳酸钾(110.6 mg, 0.8mmol),2-五氟乙基-N-3-溴-5吡啶基乙酰氯代腙(140.9 mg, 0.4 mmol),2-氧代-2-苯基乙酰亚胺乙酯(106.3 mg, 0.6 mmol),随后向体系中加入乙酸乙酯溶液(3 mL),25 ℃下搅拌20小时。薄层色谱法(TLC)检测反应完全后,硅藻土过滤除去体系中的无机盐,二氯甲烷洗涤滤渣,有机相合并,减压蒸馏除去溶剂,粗品溶于0.5 mL二氯甲烷后上样,柱层析纯化(洗脱液:石油醚/乙酸乙酯 = 150:1~80:1)可得到目标产物(1-(4-溴吡啶-3-基)-2-(五氟乙基)-1,2,4-三唑-5-基)(苯基)甲酮,黄色固体169.9 mg,产率95%。
核磁共振检测产物结构,数据如下:
1H NMR (400 MHz, CDCl3) δ 8.68 (s, 1H), 8.54–8.51 (m, 2H), 8.29–8.25(m, 2H), 7.70–7.66 (m, 1H), 7.58–7.54 (m, 2H);
19F NMR (376 MHz, CDCl3) δ -85.87 (t, J = 2.7 Hz), -115.28 (s)。
由上述实施实例可知,本发明所提供的1,5-二取代-3-氟烷基-1,2,4-三氮唑的制备方法,具有原料易得、反应条件温和、产率高、底物谱广等优点。一方面,利用本发明所提供的方法可以制备含3-氟烷基-1,2,4-三氮唑骨架的药物类似物,具有可观的应用价值;另一方面,利用本发明提供的方法合成杂环取代的1,2,4-三氮唑可用作配体参与有机反应,在有机化学和材料化学领域具有应用价值。
本发明制备的1,5-二取代-3-氟烷基-1,2,4-三氮唑,其中杂环、羰基取代的1,2,4-三氮唑可作为配体应用于各种有机反应或材料合成中;此外,本发明所提供的方法还可以用于含3-氟烷基-1,2,4-三氮唑骨架的药物类似物的制备,如下所示式(Ⅵ)和式(Ⅸ)是Celexcoxib和Deferasirox的衍生物。
Claims (10)
1.一种1,5-二取代-3-氟烷基-1,2,4-三氮唑化合物的制备方法,其特征在于,包括以下步骤:将式(Ⅰ)所示的2-氟烷基-N-取代乙酰卤代腙、式(Ⅱ)所示的取代亚氨酸酯、碱性化合物在有机溶剂中混合、反应,得到式(Ⅲ)所示的1,5-二取代-3-氟烷基-1,2,4-三氮唑;
其中,R1为取代或未取代的C6~C20的芳香基、取代或未取代的C5~C20的杂环基;所述取代或未取代的C6~C20的芳香基、取代或未取代的C5~C20的杂环基中的取代基选自C1~C5的烷基、C1~C5的烷氧基、C6~C14的芳基、C2~C24的不饱和烷基、含硫基团、氟烷基、卤素、氰基、硝基与酯基中的一种或多种;
Rf选自二氟甲基、三氟甲基或五氟乙基中的一种;
X选自氯、溴或碘中的一种;
R2为取代或未取代的C1~C6的直链烷基、取代或未取代的C3~C8的环烷基、取代或未取代的C6~C20的芳香基、取代或未取代的C5~C20的杂环基;所述取代或未取代的C1~C6的直链烷基、取代或未取代的C3~C8的环烷基、取代或未取代的C6~C20的芳香基、取代或未取代的C5~C20的杂环基中的取代基选自C1~C5的烷基、C1~C5的烷氧基、C6~C14的芳基、C2~C24的不饱和烷基、含硫基团、氟烷基、卤素、氰基、硝基与酯基中的一种或多种。
2.根据权利要求1所述的1,5-二取代-3-氟烷基-1,2,4-三氮唑化合物的制备方法,其特征在于,所述碱性化合物选自碳酸钠、碳酸钾、碳酸铯、碳酸氢钠、碳酸氢钾、醋酸钠、磷酸钾、叔丁醇钾、三乙胺中的一种或多种。
3.根据权利要求1所述的1,5-二取代-3-氟烷基-1,2,4-三氮唑化合物的制备方法,其特征在于,所述有机溶剂选自二氯甲烷、1,2-二氯乙烷、乙酸乙酯、四氢呋喃、乙醇、甲苯、乙腈、1,4-二氧六环、N,N-二甲基甲酰胺中的一种或多种。
4.根据权利要求1所述的1,5-二取代-3-氟烷基-1,2,4-三氮唑化合物的制备方法,其特征在于,反应的温度为0~120℃。
5.根据权利要求1所述的1,5-二取代-3-氟烷基-1,2,4-三氮唑化合物的制备方法,其特征在于,反应的时间为1~24h。
6.根据权利要求1所述的1,5-二取代-3-氟烷基-1,2,4-三氮唑化合物的制备方法,其特征在于,2-氟烷基-N-取代乙酰卤代腙、取代亚氨酸酯和碱性化合物的摩尔比为1:(1~5):(1~10)。
7.根据权利要求1所述的1,5-二取代-3-氟烷基-1,2,4-三氮唑化合物的制备方法,其特征在于,2-氟烷基-N-取代乙酰卤代腙与有机溶剂的用量比为0.4 mmol:2-4 mL。
9.权利要求8所述的1,5-二取代-3-氟烷基-1,2,4-三氮唑化合物在制备含3-氟烷基-1,2,4-三氮唑骨架的药物中的应用。
10.权利要求8所述的1,5-二取代-3-氟烷基-1,2,4-三氮唑化合物在作为配体参与有机反应中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211016094.2A CN115093373A (zh) | 2022-08-24 | 2022-08-24 | 一种1,5-二取代-3-氟烷基-1,2,4-三氮唑化合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211016094.2A CN115093373A (zh) | 2022-08-24 | 2022-08-24 | 一种1,5-二取代-3-氟烷基-1,2,4-三氮唑化合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115093373A true CN115093373A (zh) | 2022-09-23 |
Family
ID=83300548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211016094.2A Pending CN115093373A (zh) | 2022-08-24 | 2022-08-24 | 一种1,5-二取代-3-氟烷基-1,2,4-三氮唑化合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115093373A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999051580A1 (en) * | 1998-04-08 | 1999-10-14 | Abbott Laboratories | Pyrazole inhibitors of cytokine production |
CN101012203A (zh) * | 2002-08-07 | 2007-08-08 | Cj株式会社 | 氨基腙衍生物及其制备方法 |
CN101039922A (zh) * | 2004-10-20 | 2007-09-19 | 组合化学工业株式会社 | 3-三唑基苯基硫醚衍生物及含其作为有效成分的杀虫·杀螨·杀线虫剂 |
JP2007284356A (ja) * | 2006-04-12 | 2007-11-01 | Kumiai Chem Ind Co Ltd | 3−トリアゾリルフェニルスルフィド誘導体及びそれを有効成分として含有する農園芸用殺虫・殺ダニ・殺線虫剤 |
WO2020036133A1 (ja) * | 2018-08-17 | 2020-02-20 | クミアイ化学工業株式会社 | 3-(1h-1,2,4-トリアゾール-1-イル)安息香酸アミド誘導体及び有害生物防除剤 |
-
2022
- 2022-08-24 CN CN202211016094.2A patent/CN115093373A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999051580A1 (en) * | 1998-04-08 | 1999-10-14 | Abbott Laboratories | Pyrazole inhibitors of cytokine production |
CN101012203A (zh) * | 2002-08-07 | 2007-08-08 | Cj株式会社 | 氨基腙衍生物及其制备方法 |
CN101039922A (zh) * | 2004-10-20 | 2007-09-19 | 组合化学工业株式会社 | 3-三唑基苯基硫醚衍生物及含其作为有效成分的杀虫·杀螨·杀线虫剂 |
JP2007284356A (ja) * | 2006-04-12 | 2007-11-01 | Kumiai Chem Ind Co Ltd | 3−トリアゾリルフェニルスルフィド誘導体及びそれを有効成分として含有する農園芸用殺虫・殺ダニ・殺線虫剤 |
WO2020036133A1 (ja) * | 2018-08-17 | 2020-02-20 | クミアイ化学工業株式会社 | 3-(1h-1,2,4-トリアゾール-1-イル)安息香酸アミド誘導体及び有害生物防除剤 |
Non-Patent Citations (1)
Title |
---|
JIANN-JYH HUANG等: "One-flask synthesis of 1,3,5-trisubstituted 1,2,4-triazoles from nitriles and hydrazonoyl chlorides via 1,3-dipolar cycloaddition", 《RSC ADV.》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bellina et al. | Efficient and highly regioselective direct C-2 arylation of azoles, including free (NH)-imidazole,-benzimidazole and-indole, with aryl halides | |
Chen et al. | TBAI-catalyzed reaction between N-tosylhydrazones and sulfur: a procedure toward 1, 2, 3-thiadiazole | |
EP2537826B1 (en) | Fluorination of aromatic ring systems | |
Hoang et al. | Rhodium (III)-catalyzed C–H functionalization of C-alkenyl azoles with sulfoxonium ylides for the synthesis of bridgehead N-fused [5, 6]-bicyclic heterocycles | |
EP2334653A1 (en) | Process for the preparation of rufinamide | |
Feng et al. | General Synthesis of Tri-Carbo-Substituted N 2-Aryl-1, 2, 3-triazoles via Cu-Catalyzed Annulation of Azirines with Aryldiazonium Salts | |
Xiong et al. | One-pot and regioselective synthesis of polysubstituted 3, 4-dihydroquinazolines and 4, 5-dihydro-3H-1, 4-benzodiazepin-3-ones by sequential Ugi/Staudinger/aza-Wittig reaction | |
Ponpandian et al. | Tandem Knoevenagel-[3+ 2] cycloaddition-elimination reactions: one-pot synthesis of 4, 5-disubstituted 1, 2, 3-(NH)-triazoles | |
Zhang et al. | Base-promoted (3+ 2) cycloaddition of trifluoroacetohydrazonoyl chlorides with imidates en route to trifluoromethyl-1, 2, 4-triazoles | |
Shil et al. | Polystyrene resin supported palladium (0)(Pd@ PR) nanocomposite mediated regioselective synthesis of 4-aryl-1-alkyl/(2-haloalkyl)-1 H-1, 2, 3-triazoles and their N-vinyl triazole derivatives from terminal alkynes | |
EP1678135B1 (en) | Process for the preparation of n-amino substituted heterocyclic compounds | |
Alcarazo et al. | Synthesis, structure and electronic properties of N-dialkylamino-and N-alkoxy-1, 2, 4-triazol-3-ylidene ligands | |
Akyıldırım et al. | Novel Mannich bases derived from 1, 2, 4-triazoles: Design, synthesis, characterization, and glutathione S-transferase inhibition properties investigations | |
JP2015523985A (ja) | ジアリールヨードニウム塩を製造するための方法及び反応剤 | |
CN115093373A (zh) | 一种1,5-二取代-3-氟烷基-1,2,4-三氮唑化合物及其制备方法和应用 | |
Babu et al. | Michael addition of α-azido ketones on iminocoumarin derivatives: An efficient access to new functionalized azido chromenes | |
Wang et al. | Ring-degenerate rearrangement resulting from the azo coupling reaction of a 3-aryl-1, 3a, 6a-triazapentalene | |
KR20130061129A (ko) | 카르복시산 유도체와 엔아민의 커플링을 통한 피라졸의 합성 방법 | |
KR101879181B1 (ko) | 18f-표지 pet 방사성의약품의 전구체 및 그 제조방법 | |
CN110105285B (zh) | 三取代吡唑类衍生物及其制备方法 | |
KR20220004142A (ko) | Xp01 억제제 및 xp01 억제제의 제조에 사용하기 위한 중간체의 제조 방법 | |
Strakova et al. | Resolution, absolute configuration, and synthetic transformations of 7-amino-tetrahydroindazolones | |
CN107573298B (zh) | 一种合成2,5-二取代恶唑化合物的制备方法 | |
CN110845486B (zh) | 一种三氮唑醇类衍生物及其制备方法和应用 | |
Gu et al. | An Efficient One‐pot Synthesis of Aryl‐substituted 1‐(Thiazol‐2‐yl)‐1H‐pyrazole‐3‐carboxylates via a Hantzsch Synthesis‐Knorr Reaction Sequence |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220923 |
|
RJ01 | Rejection of invention patent application after publication |